Oleandrin (PBI-05204)

Oleandrin, also known as PBI-05204 , is a lipid soluble cardiac glycoside with potential antineoplastic activity. Upon administration, oleandrin specifically binds to and inhibits the alpha3 subunit of the Na/K-ATPase pump in human cancer cells. This may inhibit the phosphorylation of Akt, upregulate MAPK, inhibit NF-kb activation and inhibit FGF-2 export and may downregulate mTOR thereby inhibiting p70S6K and S6 protein expression. All of this may lead to an induction of apoptosis.

Properties:

Density: 1.261g/cm3

Boiling Point: 693.669ºC at 760 mmHg

Melting Point: 250ºC

Flash Point: 217.166ºC

Refractive Index: 1.567

ATPase Inhibitors Related Products:

Omecamtiv mecarbil; Brefeldin A; Lansoprazole; PF-03716556; Dexlansoprazole; CB-5083; Bedaquiline; Bafilomycin A1; Tamoxifen; Esomeprazole sodium; Oligomycin A

[1]. Jortani SA, et al. Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem. 1996 Oct;42(10):1654-8.

[2]. Yang P, et al. Cellular location and expression of Na⁺, K⁺-ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 2014 Apr;53(4):253-63.